MARKET WIREYahoo Finance • 22h ago
Lisata Therapeutics wins new US patent for pancreatic cancer drugYahoo Finance report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
Why LSTA Stock slipped -0.98% Today — RQD Quant Desk Flash
$1.01 -0.98% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.01
Lisata Therapeutics Inc. (LSTA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $11.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on LSTA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is LSTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Lisata Therapeutics Inc. (NASDAQ: LSTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.01 (-0.98% 1D, market cap $11.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LSTA ranks #848 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does LSTA compare to GTBP and GDTC in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LSTA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GTBP (GT Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, LSTA leads on earnings multiple (N/A) while LSTA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for LSTA?
▼
Per LSTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000320017), Lisata Therapeutics Inc. generated $170.0K in revenue (-83.0% YoY), -$17.0M in net income, and -$16.0M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.01 (-0.37%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-12.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for LSTA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY LSTA SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+8/20 pts (28% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (28% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$1.08-3.7% Next Q
37
Q2 (-2Q)Grade E$1.04-1.9% Next Q
34
Q3 (-1Q)Grade E$1.02-1% Next Q
32
CurrentGrade E$1.01-9.8% Hist 90D α
29
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a LSTA Turnaround Squeeze
While LSTA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.37) and Max Pain ($1.06) forces dealer call-delta covering toward $5.32.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $LSTA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “LSTA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why LSTA Stock slipped -0.98% Today — RQD Quant Desk Flash
Lisata Therapeutics Inc. (LSTA) slipped -0.98% to $1.01, trading at 2% of its 52-week range ($0.96 – $5.07). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($0.96 – $5.07) with RSI-14 at 39.1 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.01 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live LSTA Headlines & Catalysts
MARKET WIREStocktwits • 1d ago
Lisata Therapeutics Inc (LSTA) sentiment score, message volume, participation score and buzz levelStocktwits report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
LISATA THERAPEUTICS, INC. SEC Filing (Oct 19, 2026)Stock Titan report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Lisata Therapeutics Announces New Method of Use PatentGlobeNewswire report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Lisata Therapeutics, Inc. (LSTA) Stock Price, News, Quote & HistoryYahoo Finance report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Daily Tribune News • 1d ago
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their ShareholdersThe Daily Tribune News report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Manila Times • 1d ago
Lisata Therapeutics Appoints Jeff Farrow to Board of DirectorsThe Manila Times report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
MARKET WIREGlobeNewswire • 1d ago
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of AcromegalyGlobeNewswire report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo • 19d ago
Lisata adds biopharma finance veteran Jeffrey Farrow to boardLisata Therapeutics Inc (NASDAQ:LSTA, FRA:8NE) said it has appointed Jeffrey Farrow, a veteran biopharma finance executive, to its board of directors. Farrow fills a newly created seat, expanding the board from seven to
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring LSTA)
- ✓Walkthrough of LSTA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
LSTA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -69.85%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.01H $1.02L $1.01C $1.01VOL 60.8K
RES: $1.62SUP: $0.96SMA50: $1.37SMA200: $2.98
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
LSTA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth
vs. -83.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger
No active Ellis Vennor swing setup published on LSTA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for LSTA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for LSTA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (LSTA)
Health Care Rank #848 of 1015
⚔️ GTBP vs LSTA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (LSTA vs. GTBP, GDTC, ASBP, CLRB)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1015 tracked Health Care securities in the Roarable RQD universe, Lisata Therapeutics Inc. (LSTA) ranks #848 by composite RQD confidence (29/100, grade E) and #884 by equity capitalization ($11.0M). Within this direct 5-issuer industry benchmark cohort, LSTA leads on earnings valuation at N/A trailing P/E, while LSTA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. GDTC currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with LSTA at 29/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| LSTA
ACTIVE
Lisata Therapeutics Inc. | E | 29/100 | — | — | -35.0% | -0.98% | $11.0M | Benchmark Subject |
| GTBP GT Biopharma Inc. | D- | 36/100 | — | — | -35.0% | -3.57% | $11.0M | /gtbp-vs-lsta → |
| GDTC CytoMed Therapeutics Limited | D+ | 52/100 | — | — | — | -0.98% | $10.9M | /gdtc-vs-lsta → |
| ASBP Aspire-Lakewood Holdings Inc. | D- | 40/100 | — | -1.9% | -35.0% | -9.99% | $11.4M | /asbp-vs-lsta → |
| CLRB Cellectar Biosciences Inc. | E | 32/100 | — | — | -35.0% | +1.25% | $11.4M | /clrb-vs-lsta → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000320017 ↗In its most recent audited fiscal period (FY2025, filed 2025-12-31), Lisata Therapeutics Inc. (LSTA) reported GAAP revenue of $170.0K (-83.0% vs. FY2024 revenue of $1.0M , and -99.8% cumulative change since FY2023) , GAAP net income of -$17.0M, operating cash flow of -$15.9M, and free cash flow of -$16.0M (+17.5% YoY). On the balance sheet, LSTA closed FY2025 with $17.7M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $170.0K | -$17.0M | -$15.9M | -$16.0M | $17.7M | — |
| FY2024 (FY) | 2024-12-31 | $1.0M | -$20.0M | -$19.4M | -$19.4M | $35.0M | — |
| FY2023 (FY) | 2023-12-31 | $72.0M | -$21.0M | -$20.0M | -$20.0M | — | — |
3. LSTA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs LSTA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Lisata Therapeutics Inc. (NASDAQ: LSTA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $1.01 (-0.98% 1D, market cap $11.0M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 7/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, LSTA ranks #848 in composite RQD confidence.
How does LSTA compare to GTBP and GDTC in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), LSTA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, GTBP (GT Biopharma Inc.) holds a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $11.0M) and GDTC (CytoMed Therapeutics Limited) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $10.9M). Among the 5-stock peer group, LSTA leads on earnings multiple (N/A) while LSTA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for LSTA?
Per LSTA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000320017), Lisata Therapeutics Inc. generated $170.0K in revenue (-83.0% YoY), -$17.0M in net income, and -$16.0M in free cash flow against $17.7M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.
Where is LSTA trading relative to its 50-day, 200-day, and 52-week technical levels?
LSTA last traded at $1.01 (-0.98% on volume of 97,152 shares), positioning the stock -26.28% below its 50-day simple moving average ($1.37) and -66.11% below its 200-day simple moving average ($2.98). Across its 52-week range of $0.96 to $5.07, LSTA sits at the 1.2% percentile with a 14-day RSI of 39.1 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $1.14).
ROARABLE RATING BRIEF • RQD 29/100 (E)
✓ SEC XBRL & RQD VERIFIED
LSTA — Lisata Therapeutics Inc.: What the Facts Mean to a Prospective Investor
Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31
1. Roarable Rating Brief: What This Means to a Prospective Investor
Lisata Therapeutics Inc. (LSTA) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.01 (-0.98% 1D, market capitalization $11.0M).
- Fundamental Cash Engine (8/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of -60.0%, and free cash flow yield of —.
- Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
- Macro Regime Fit (7/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 3/9, and Debt/Equity of N/A.
2. Business Model, Unit Margins & SEC Financial Trajectory
Lisata Therapeutics Inc. (LSTA) is a NASDAQ-listed operating company in the Biotechnology: Pharmaceutical Preparations industry (Health Care sector) with an equity market capitalization of $11.0M. The business operates with a gross margin of 0%, an operating margin of -60%, and a return on invested capital (ROIC) of -35% (free cash flow yield of 0%). Within the Biotechnology: Pharmaceutical Preparations peer group, investor evaluation centers on operating leverage, unit margin durability, and capital allocation efficiency across market cycles.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Lisata Therapeutics Inc. (LSTA) reported $170.0K in annual revenue (up from $1.0M in FY2024, -83.0% YoY) and -$17.0M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($72.0M revenue, -$21.0M net income) through FY2025, LSTA scaled operating cash flow to -$15.9M and free cash flow to -$16.0M, backed by $17.7M in total assets against $0 in total debt.
3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff
- 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 3/20. With Fundamental Cash Engine at 8/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $0.96 – $5.07 52-week range.
- 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.
4. 2nd-Order Butterfly Ripples & Key Questions to Watch
— Upstream and downstream dependencies, sector correlations beyond the stated beta of 1.0, and second-order bottlenecks cannot be determined from the source data.
- Key Question #1: Can LSTA sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
- Key Question #2: Following FY2025 revenue of $170.0K and free cash flow of -$16.0M, how will capital allocation balance growth reinvestment against $0 in total debt?
- Key Question #3: How sensitive is LSTA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?
LSTA Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Lisata Therapeutics Inc. (LSTA) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 22h ago
Lisata Therapeutics wins new US patent for pancreatic cancer drug Yahoo Finance report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stocktwits • 1d ago
Lisata Therapeutics Inc (LSTA) sentiment score, message volume, participation score and buzz level Stocktwits report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
LISATA THERAPEUTICS, INC. SEC Filing (Oct 19, 2026) Stock Titan report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Lisata Therapeutics Announces New Method of Use Patent GlobeNewswire report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Lisata Therapeutics, Inc. (LSTA) Stock Price, News, Quote & History Yahoo Finance report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Daily Tribune News • 1d ago
Halper Sadeh LLC is Investigating Whether BWIN, LSTA, ACVA are Obtaining Fair Deals for their Shareholders The Daily Tribune News report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Manila Times • 1d ago
Lisata Therapeutics Appoints Jeff Farrow to Board of Directors The Manila Times report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE GlobeNewswire • 1d ago
Marea Therapeutics, a Subsidiary of Lisata Therapeutics, Announces First Patient Dosed in Phase 2 Clinical Trial of MAR002, a Potential Best-in-disease Investigational Therapy for the Treatment of Acromegaly GlobeNewswire report covering Lisata Therapeutics Inc. (LSTA) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
LSTA Bull vs. Bear Conversation Board — What's Your Call at $1.01?
🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON LSTA 🐻 33% BEARISH CONVICTION
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH
🎯 Target: $1.17 (+14.7%)
📌 Pinned Debate A newly reported US patent for a pancreatic cancer drug is the only positive catalyst in the news wire.
A newly reported US patent for a pancreatic cancer drug is the only positive catalyst in the news wire.. When you look under the hood at LSTA, Fundamental Cash Engine is 8/20 with 0.0% gross margins and -35.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (3/20) has been quietly accumulating below $5.07. My 12M target is $1.17.
EarningsSniper 🐂 BULL
@ForensicBear Shorting a 3/20 institutional whale-flow stock at $1.02 is dangerous when funds are rotating into Health Care.
FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH
🎯 Target: $0.77 (-24.5%)
Spot @ $1.02 A 29/E RQD score with 0% FCF yield and -35% ROIC, against FY 2025 cash of $16.0M versus FCF of -$16.0M, signals limited runway and fore
Here is the bear case nobody on the bull side wants to address on LSTA: A 29/E RQD score with 0% FCF yield and -35% ROIC, against FY 2025 cash of $16.0M versus FCF of -$16.0M, signals limited runway and forensic risk.. At current EV/EBITDA multiples, even a small guidance miss in Biotechnology: Pharmaceutical Preparations triggers a 12-15% air pocket.